Loading organizations...
§ Private Profile · Wilmington, DE, USA
Synnovation Therapeutics is a technology company.
Synnovation Therapeutics develops best-in-class small molecule targeted therapies in precision medicine. The company uses advanced medicinal chemistry to engineer compounds with optimized pharmacology, focusing on validated disease targets, primarily in oncology. This approach leverages deep expertise to deliver superior therapeutic options, aiming for significant clinical benefits.
Founded in 2021, Synnovation Therapeutics was established by an accomplished team of medicinal chemists from the biopharmaceutical industry. These founders brought extensive drug discovery experience and a proven track record, driven by the insight that novel small molecules could improve patient outcomes in areas of high unmet medical need. This collective expertise underpins the company’s foundation.
Synnovation Therapeutics aims to provide effective, precisely acting treatments for patients with challenging diseases, especially in oncology. Its vision is to improve patient quality of life and clinical prognosis through an innovative therapeutic portfolio. The company commits to advancing precision medicine, continually developing therapies with superior efficacy and safety.
Synnovation Therapeutics has raised $100.0M across 1 funding round.
Synnovation Therapeutics has raised $100.0M in total across 1 funding round.
Synnovation Therapeutics has raised $100.0M across 1 funding round. Most recently, it raised $100.0M Series A in December 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2023 | $100M Series A | Third Rock Ventures | Johnson & Johnson Innovation, Sofinnova Investments, Cormorant Asset Management, Judith LI, Thilo Schroeder, Ting Feng | Announced |
Synnovation Therapeutics is a precision oncology company developing small molecule therapies that target key driver mechanisms in cancers to advance patient-focused precision medicine.[1][2][3] Founded in 2021 in Wilmington, Delaware, it leverages expertise in cancer biology and medicinal chemistry to build a diverse pipeline of best-in-class and first-in-class therapeutics, aiming to efficiently move them into clinical trials and transform cancer care.[1][2][3] The company serves cancer patients by addressing unmet needs through innovative targeted treatments, with strong growth momentum including a Series A funding round of $102M (total funding $139M as of December 2023) and plans to expand its workforce from around 30 to over 70 by 2026, creating 44 high-paying jobs in Delaware.[3][4]
Synnovation Therapeutics was founded in 2021 in Wilmington, Delaware, by Wenqing Yao, a founding scientist from Incyte, drawing on deep experience in oncology drug development.[3][4] Key early leaders include Executive Director Hui Wang, who previously served as associate director of small molecule therapy oncology programs at Incyte, highlighting the team's roots in established pharma innovation.[5] The idea emerged from expertise in cancer biology and medicinal chemistry, leading to rapid early traction: since launch, the company has advanced its portfolio of targeted oncology molecules and secured significant Series A funding led by investors like Cormorant Asset Management, Lilly Asia Ventures, Third Rock Ventures, Nextech Invest, and Sirona Capital in December 2023.[3][4] Operating from The Innovation Space near Wilmington, this Delaware-founded biotech has steadily grown its team while positioning itself as a leader in precision medicine.[3]
Synnovation rides the precision medicine trend in oncology, where targeted small molecule therapies outperform traditional treatments by focusing on specific cancer drivers, amid rising demand for personalized cancer care.[1][2][3] Timing is ideal post-2021 founding, capitalizing on post-pandemic biotech investment surges and regional strengths in pharma innovation like Incyte's legacy in Delaware.[3][5] Market forces favoring it include U.S. life sciences growth, with Delaware's ecosystem supporting expansion, and broader tailwinds in oncology R&D driven by aging populations and unmet needs in hard-to-treat cancers.[3][4] By advancing its pipeline, Synnovation influences the ecosystem as a job creator and innovator, bolstering the Delaware-Philadelphia region's status as a precision medicine center.[3]
Synnovation is poised to advance its pipeline into clinical trials, potentially yielding breakthroughs in targeted oncology therapies amid accelerating precision medicine adoption.[1][2][3] Trends like AI-enhanced drug discovery and combination therapies will shape its path, with workforce doubling by 2026 signaling aggressive scaling.[3][4] Its influence may evolve from early-stage innovator to clinical leader, further solidifying Delaware's biotech prominence—transforming science into life-improving cancer treatments as promised.[1][3]
Synnovation Therapeutics has raised $100.0M in total across 1 funding round.
Synnovation Therapeutics's investors include Third Rock Ventures, Johnson & Johnson Innovation, Sofinnova Investments, Cormorant Asset Management, Judith Li, Thilo Schroeder, Ting Feng.